Safety and Efficacy of First-Line Bevacizumab with Chemotherapy in Asian Patients with Advanced Nonsquamous NSCLC: Results from the Phase IV MO19390 (SAiL) Study

Wang, 2006, Lung cancer epidemiology in mainland China, Chin J Clin Oncol, 3, 244, 10.1007/s11805-006-0050-z Wu, 2007, Lung cancer management in the Asia-Pacific region: what's the difference compared with the United States and Europe? Results of the Second Asia Pacific Lung Cancer Conference, J Thorac Oncol, 2, 574, 10.1097/01.JTO.0000275341.39960.6c Gu, 2009, Mortality attributable to smoking in China, N Engl J Med, 360, 150, 10.1056/NEJMsa0802902 Molina, 2008, Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship, Mayo Clin Proc, 83, 584, 10.1016/S0025-6196(11)60735-0 Sandler, 2006, Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer, N Engl J Med, 355, 2542, 10.1056/NEJMoa061884 Reck, 2009, Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for non-squamous non-small-cell lung cancer: AVAiL, J Clin Oncol, 27, 1227, 10.1200/JCO.2007.14.5466 Chouaid, 2009, Economics of treatments for non-small cell lung cancer, Pharmacoeconomics, 27, 113, 10.2165/00019053-200927020-00003 Bischoff, 2010, Costs of bevacizumab and pemetrexed for advanced non-squamous NSCLC in Italy and Germany, Lung Cancer, 69, S18, 10.1016/S0169-5002(10)70134-3 Giuliani, 2010, Cost-effectiveness analysis of bevacizumab versus pemetrexed for advanced non-squamous NSCLC in Italy, Lung Cancer, 69, S11, 10.1016/S0169-5002(10)70133-1 Crinò, 2010, Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study, Lancet Oncol, 11, 733, 10.1016/S1470-2045(10)70151-0 Mok, 2010, Efficacy and safety of erlotinib in 1242 East/South-East Asian patients with advanced non-small cell lung cancer, J Thorac Oncol, 5, 1609, 10.1097/JTO.0b013e3181e15d55 Shepherd, 2005, Erlotinib in previously treated non-small-cell lung cancer, N Engl J Med, 353, 123, 10.1056/NEJMoa050753 Jiang, 2009, Overview of gefitinib in non-small cell lung cancer: an Asian perspective, Jpn J Clin Oncol, 39, 137, 10.1093/jjco/hyn139 Nishio, 2009, Randomized, open-label, multicenter phase II study of bevacizumab in combination with carboplatin and paclitaxel in chemotherapy-naive Japanese patients with advanced or recurrent nonsquamous non-small cell lung cancer (NSCLC): JO19907, J Clin Oncol, 27, 15s, 10.1200/jco.2009.27.15_suppl.8036 Reck, 2010, Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL), Ann Oncol, 21, 1804, 10.1093/annonc/mdq020 Sandler, 2010, Treatment outcomes by tumor histology in Eastern Cooperative Group (ECOG) study E4599 of bevacizumab with paclitxel/carboplatin for advanced non-small cell lung cancer (NSCLC), J Thorac Oncol, 5, 1416, 10.1097/JTO.0b013e3181da36f4 Pirker, 2009, Centuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial, Lancet, 373, 1525, 10.1016/S0140-6736(09)60569-9 Sy, 2003, Genetic alterations of lung adenocarcinoma in relation to smoking and ethnicity, Lung Cancer, 41, 91, 10.1016/S0169-5002(03)00138-7 Ou, 2009, Asian ethnicity is a favorable prognostic factor for overall survival in non-small cell lung cancer (NSCLC) and is independent of smoking status, J Thorac Oncol, 4, 1083, 10.1097/JTO.0b013e3181b27b15 Kawaguchi, 2010, J Thorac Oncol, 5, 1001, 10.1097/JTO.0b013e3181e2f607 Mok, 2009, Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma, N Engl J Med, 361, 947, 10.1056/NEJMoa0810699